Nintedanib alleviates pulmonary inflammation and fibrosis in mice with silicosis.
5 affiliations
- 1Department of Pneumoconiosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Yangpu District, Shanghai, 200433, China.
- 22nd People's Hospital of Shanxi Province, 9 West Kouzhuang Rd., Taiyuan, Shanxi Province, 030012, China.
- 3Department of Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Rd., Shanghai, 200433, China.
- 4Department of Respiratory and Pneumoconiosis, 2nd People's Hospital of Shanxi Province, 9 West Kouzhuang Rd., Taiyuan, Shanxi Province, 030012, China. [email protected].
- 5Department of Pneumoconiosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Yangpu District, Shanghai, 200433, China. [email protected].
Abstract
Objective
This study aimed to evaluate nintedanib's therapeutic effects on mice silicosis by examining pulmonary function, lung inflammation, and fibrosis.Methods
Mice were categorized into preventive and therapeutic groups, each with control, low-dose, and high-dose treatment subgroups. Cell counts in bronchoalveolar lavage fluid and cytokines in the lung tissue were detected using quantitative polymerase chain reaction. The right ventricular hypertrophy index (RVHI) was assessed, and lung collagen deposition and inflammation were analyzed using various histological and molecular techniques. Forced lung function tests were conducted to evaluate lung compliance, total lung capacity (TLC), and the mouse airway resistance.Results
In the preventive group, neutrophil counts and levels of pro-inflammatory cytokines in lung tissue were significantly lower in the treatment group than in the control group, with no significant differences in the RVHI. Collagen deposition and pathological scores for inflammation and fibrosis were reduced in the treatment group. In lung function tests, TLC was higher and resistance lower in the high-dose group. In the therapeutic group, cytokine levels and the RVHI were significantly lower in the treatment group, while collagen type I mRNA expression was statistically significant. Lung function tests revealed improved TLC and resistance in the treatment group.Conclusion
Nintedanib reduces lung inflammation, fibrosis, and right ventricular hypertrophy in mice with silicosis, demonstrating potential therapeutic effects.
Related
- Remote ischemic conditioning mitigates diesel exhaust-induced pulmonary fibrosis by alleviating pulmonary inflammation and fibrogenesis
- Magnolol alleviates high-fat diet-induced steatosis, inflammation and fibrosis in obesity-associated liver injuries via MOGAT1-mediated lipid metabolism and NF-κB signaling
- Integrative network toxicology and pharmacology reveal that kaempferol alleviates BaP-triggered pulmonary fibrosis via suppressing Ras/COX-2-dependent cellular senescence
- GABABR activation alleviates Streptococcus equi subsp. zooepidemicus-induced acute lung injury by suppressing inflammation and oxidative stress in pulmonary macrophages via IRAK3
- Crocin alleviates renal fibrosis through inhibiting mitochondrial dysfunction via regulating HOXD8/PGC‑1α pathways
BibTeX
@article{huang2026nintedanib,
title = {{Nintedanib alleviates pulmonary inflammation and fibrosis in mice with silicosis.}},
author = {Limin Huang and Li Liu and Liang Tang and Hongxia Tian and Ling Mao},
journal = {BMC pulmonary medicine},
year = {2026},
month = jul,
doi = {10.1186/s12890-026-04546-y},
url = {https://europepmc.org/article/MED/42907787},
note = {CC BY},
}
RIS
TY - JOUR
TI - Nintedanib alleviates pulmonary inflammation and fibrosis in mice with silicosis.
AU - Limin Huang
AU - Li Liu
AU - Liang Tang
AU - Hongxia Tian
AU - Ling Mao
PY - 2026
DA - 2026/07/01
JO - BMC pulmonary medicine
DO - 10.1186/s12890-026-04546-y
UR - https://europepmc.org/article/MED/42907787
AB - Objective This study aimed to evaluate nintedanib's therapeutic effects on mice silicosis by examining pulmonary function, lung inflammation, and fibrosis.Methods Mice were categorized into preventive and therapeutic groups, each with control, low-dose, and high-dose treatment subgroups. Cell counts in bronchoalveolar lavage fluid and cytokines in the lung tissue were detected using quantitative polymerase chain reaction. The right ventricular hypertrophy index (RVHI) was assessed, and lung collagen deposition and inflammation were analyzed using various histological and molecular techniques. Forced lung function tests were conducted to evaluate lung compliance, total lung capacity (TLC), and the mouse airway resistance.Results In the preventive group, neutrophil counts and levels of pro-inflammatory cytokines in lung tissue were significantly lower in the treatment group than in the control group, with no significant differences in the RVHI. Collagen deposition and pathological scores for inflammation and fibrosis were reduced in the treatment group. In lung function tests, TLC was higher and resistance lower in the high-dose group. In the therapeutic group, cytokine levels and the RVHI were significantly lower in the treatment group, while collagen type I mRNA expression was statistically significant. Lung function tests revealed improved TLC and resistance in the treatment group.Conclusion Nintedanib reduces lung inflammation, fibrosis, and right ventricular hypertrophy in mice with silicosis, demonstrating potential therapeutic effects.
SN - 1471-2466
ER -